Malignant Melanoma | Current Treatment: Physician Insights | EU5 | 2016
Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced by disease stage, resectability, and in the unresectable or metastatic setting, BRAF-mutation status. The malignant melanoma landscape has transformed since 2011: CTLA-4 inhibitors, PD-1 inhibitors, and BRAF/MEK inhibitors are now key treatment options for unresectable disease while adjuvant cytokine therapy remains the mainstay for early-stage disease. This analysis provides insight on current use of approved therapies for malignant melanoma in the EU5 and on factors driving physicians’ prescribing decisions.
Related Market Assessment Reports
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
